TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03351075

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard physical therapy program
Description: Mobilisations, stretching, scar tissue treatment and exercises~* Start immediately after surgery, sessions are individual and take 30 minutes~* Intensive phase (4 months): 1-2x/week~* Maintenance phase (8 months, 3 sessions): 6, 8 and 12 months post-surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard physical therapy program
Description: Mobilisations, stretching, scar tissue treatment and exercises~* Start immediately after surgery, sessions are individual and take 30 minutes~* Intensive phase (4 months): 1-2x/week~* Maintenance phase (8 months, 3 sessions): 6, 8 and 12 months post-surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modern educational program
Description: This modern neuroscience educational approach is suited to explain more complex issues associated with pain such as the involvement of peripheral and central mechanisms, neuroplasticity and pain behaviour.~* Sessions are individual and take 30 minutes, in addition to the standard physical therapy sessions~* 3 sessions during week 1-2, 3 booster sessions at 6, 8 and 12 months post-surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional biomedical educational program
Description: Traditional educational interventions are applied according to the biomedical model. This means that the patient's pain experience is explained from a tissue (injured versus healthy tissue) and biomechanics perspective~* Sessions are individual and take 30 minutes, in addition to the standard physical therapy sessions~* 3 sessions during week 1-2, 3 booster sessions at 6, 8 and 12 months post-surgery
Study: NCT03022994

Intervention type: OTHER
Intervention: Duodenum and rectum examination
Description: All subjects will undergo upper gastrointestinal endoscopy and proctoscopy. In addition, it will be also evaluated duodenal and rectal biopsies.

Intervention type: OTHER
Intervention: Duodenum and rectum examination
Description: All subjects will undergo upper gastrointestinal endoscopy and proctoscopy. In addition, it will be also evaluated duodenal and rectal biopsies.
Study: NCT02198469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Er:YAG AFL-PDT
Description: Er:YAG AFL was performed with 350 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. MAL cream was then applied under occlusion for 3 hrs and illuminated with a red light-emitting diode light at 37 J/cm2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MAL-PDT
Description: a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm-2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later.
Study: NCT02002845

Intervention type: DEVICE
Intervention: robotic surgery using the da Vinci Surgical System
Study: NCT04194710

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Cytokine Rich Serum
Description: Proteins, called cytokines, released from blood platelets and leukocytes, play an important role in the repair and regeneration of the injured tissue that causes lateral epicondylitis.~Autologous Cytokine Rich Serum is prepared by the medical devise Q-Cytokine (CE MED31489) from patient's blood. The company Tecnologia Regenerativa Qrem S.L., with licence number 7096-PS from Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), is the manufacturer of this product. Q-Cytokine is a lab-in-a-box devise, and consist of an automatic centrifuge and a sterile disposable kit. After 9 steps of centrifugation, that take place in 36 minutes, Cytokine Rich Serum is obtained. This Cytokine Rich Serum is then injected to the epicondyle.~Patients randomized to this treatment will receive 1 injections of Autologous Cytokine Rich Serum right after randomization and another one after 15 days.~This process will take place at outpatient clinics.
Study: NCT03606655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kava
Description: Kava: 75 mg three times daily (3 capsules)
Study: NCT02584023

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lung ultrasound
Description: Lung ultrasound on both hemithorax in supine position

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Lung ultrasound
Description: Lung ultrasound on both hemithorax in supine position
Study: NCT04194710

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic Resection
Description: Surgical treatment of resection by arthroscopy is the standard treatment for chronic epicondylitis. The surgery is performed in the operating room under local anesthesia and lasts approximately 30 minutes. During the surgery, the doctor accesses the tendon by arthroscopy to perform an exeresis of the degenerated tendon. After the operation, the patient is directed to the recovery room where the responsible doctor will perform a physical examination and examination before leaving the center.~This process will take place at the major ambulatory surgery center of the investigator's hospital.
Study: NCT02465294

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral lifestyle intervention
Description: All participants will participate in weekly group meetings of 15 to 20 participants for a facilitated discussion of specific nutritional, behavioral, and physical activity topics chosen to promote weight loss.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This group will receive the placebo and will be taken as a capsule once daily for 12 weeks. The placebo will contain encapsulated potato starch which is used the matrix in the probiotic supplements.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Test
Description: All subjects will have blood tests performed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Test
Description: All subjects will have blood tests performed.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Blood Test
Description: All subjects will have blood tests performed.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: This group will receive the blend of Bifidobacterium and Lactobacillus probiotic, which will be taken as a capsule once daily for 12 weeks.
Study: NCT04126590

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KN044
Description: The modified phase I 3 + 3 study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of KN044: 0.03mg/kg,0.3 mg/kg,1 mg/kg,3 mg/kg,6 mg/kg,10 mg/kg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KN044
Description: The modified phase I 3 + 3 study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of KN044: 0.03mg/kg,0.3 mg/kg,1 mg/kg,3 mg/kg,6 mg/kg,10 mg/kg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KN044
Description: The modified phase I 3 + 3 study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of KN044: 0.03mg/kg,0.3 mg/kg,1 mg/kg,3 mg/kg,6 mg/kg,10 mg/kg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KN044
Description: The modified phase I 3 + 3 study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of KN044: 0.03mg/kg,0.3 mg/kg,1 mg/kg,3 mg/kg,6 mg/kg,10 mg/kg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KN044
Description: The modified phase I 3 + 3 study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of KN044: 0.03mg/kg,0.3 mg/kg,1 mg/kg,3 mg/kg,6 mg/kg,10 mg/kg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KN044
Description: The modified phase I 3 + 3 study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of KN044: 0.03mg/kg,0.3 mg/kg,1 mg/kg,3 mg/kg,6 mg/kg,10 mg/kg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KN044
Description: The modified phase I 3 + 3 study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of KN044: 0.03mg/kg,0.3 mg/kg,1 mg/kg,3 mg/kg,6 mg/kg,10 mg/kg.
Study: NCT04122144

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENHANCED -SPS intervention
Description: a) Enhanced VL counseling: Explanation of VL \& Importance of VL suppression,assessment of adherence, counseling based on VL result and schedule for next VL testing and the role of VL and the MTCT risk; b).Standardized peer mother support: includes training of peer mothers on mandatory enhanced VL counseling during the routine peer counseling and education, follow up of mothers and continued adherence counseling and disclosure support and bi-weekly phone calls to mothers to provide VL counseling and follow up
Study: NCT03925350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: 300 mg PO daily
Study: NCT02616965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Romidepsin at the dosage 10mg/m2 or 14mg/m2 will be given ONCE 14 days prior to cycle one and then on days 1,8,15 in each cycle. Each cycle is 28 days and treatment will continue up to 16 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: Brentuximab vedotin at the dosage 0.9mg/kg or 1.2 mg/kg will be given on days 1 and 15 in each cycle. Each cycle is 28 days and treatment will continue up to 16 cycles
Study: NCT03425695

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CheseeTM Diode Laser
Description: low level laser therapy was utilized adjunct with free gingival graft.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CheseeTM Diode Laser
Description: low level laser therapy was utilized adjunct with free gingival graft.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Clinical examination
Description: The shrinkage of the graft area was calculated according to the differences between the graft area at baseline, 1st, 3rd, and 6th months.~Epithelization was determined via bubbling test by using 3% hydrogen peroxide (H2O2) at 7, 14, 21, and 28 days after surgery.
Study: NCT01524926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib (PF-02341066)
Description: For patients of 15yo and older, Capsules of 200 and 250 mg Daily dose of 500, 400 or 250 mg/day depending on toxicitie; for patients younger than 15yo, 280 mg/m²/dose BID, with reductions allowed to 80% as first reduction and to 60% as second reduction respectively of the initial dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib (PF-02341066)
Description: For patients of 15yo and older, Capsules of 200 and 250 mg Daily dose of 500, 400 or 250 mg/day depending on toxicitie; for patients younger than 15yo, 280 mg/m²/dose BID, with reductions allowed to 80% as first reduction and to 60% as second reduction respectively of the initial dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib (PF-02341066)
Description: For patients of 15yo and older, Capsules of 200 and 250 mg Daily dose of 500, 400 or 250 mg/day depending on toxicitie; for patients younger than 15yo, 280 mg/m²/dose BID, with reductions allowed to 80% as first reduction and to 60% as second reduction respectively of the initial dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib (PF-02341066)
Description: For patients of 15yo and older, Capsules of 200 and 250 mg Daily dose of 500, 400 or 250 mg/day depending on toxicitie; for patients younger than 15yo, 280 mg/m²/dose BID, with reductions allowed to 80% as first reduction and to 60% as second reduction respectively of the initial dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib (PF-02341066)
Description: For patients of 15yo and older, Capsules of 200 and 250 mg Daily dose of 500, 400 or 250 mg/day depending on toxicitie; for patients younger than 15yo, 280 mg/m²/dose BID, with reductions allowed to 80% as first reduction and to 60% as second reduction respectively of the initial dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib (PF-02341066)
Description: For patients of 15yo and older, Capsules of 200 and 250 mg Daily dose of 500, 400 or 250 mg/day depending on toxicitie; for patients younger than 15yo, 280 mg/m²/dose BID, with reductions allowed to 80% as first reduction and to 60% as second reduction respectively of the initial dose.
Study: NCT02708004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprocitentan
Description: Formulated in capsules in 2 different strengths; 2 capsules per day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching active drug
Study: NCT03083106

Intervention type: DEVICE
Group type: OTHER
Intervention: Elevoplasty
Description: The Elevo™ Kit Snoring Intervention Device is designed to facilitate deployment of the Elevo™ suture implant into the submucosal tissue of the soft palate via a minimally invasive, outpatient procedure performed by an otolaryngologist in a medical office setting.
Study: NCT01427660

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community Health Worker Diabetes Education: Print media
Description: Providing information to patients about potential benefits, harms, costs, and burdens of medications and discussing patients' treatment preferences.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHW Diabetes Education: tailored web site
Description: Providing tailored and interactive information to patients about potential benefits, harms, costs, and burdens of medications and discussing patients' treatment preferences.
Study: NCT04490265

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-solving treatment
Description: included in arm descriptions

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Supportive Psychotherapy
Description: included in arm descriptions
Study: NCT01720693

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypoperfusion of renal artery
Description: The renal artery is occluded to 30% of it's baseline, prior to kidney tumour removal
Study: NCT03425695

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical examination
Description: The shrinkage of the graft area was calculated according to the differences between the graft area at baseline, 1st, 3rd, and 6th months.~Epithelization was determined via bubbling test by using 3% hydrogen peroxide (H2O2) at 7, 14, 21, and 28 days after surgery.
Study: NCT04497948

Intervention type: DRUG
Group type: OTHER
Intervention: Acalabrutinib
Description: Acalabrutinib (CALQUENCE®) is a covalent BTK inhibitor
Study: NCT00866658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Self-administered by subcutaneous injections once daily within the hour preceding breakfast.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Self-administered by subcutaneous injections once daily within the hour preceding breakfast.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pen auto-injector

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pen auto-injector

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfonylurea
Description: Sulfonylurea if given, to be continued at a stable dose.
Study: NCT02839044

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Menaquinone-7

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00940849

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant sterol containing drink
Description: The test products used in the study will be a commercially available PS drink and a ready to eat macaroni meal

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard macaroni meal
Description: The test products used in the study will be a commercially available PS drink and a ready to eat macaroni meal
Study: NCT02766972

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rapid Ventricular Pacing
Description: Use of Rapid Ventricular Pacing to improve surgical clipping of intracranial aneurysms
Study: NCT02410590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Study: NCT00866658

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sulfonylurea
Description: Sulfonylurea if given, to be continued at a stable dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basal Insulin
Description: To be continued at a stable dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Basal Insulin
Description: To be continued at a stable dose.
Study: NCT03058094

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed will be administered as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle. Folic acid will be administered 1-2 weeks prior to the 1st dose, then daily during the treatment period until 21days post the last dose. Vitamin B12 will be administered on the same day of pemetrexed infusion during the treatment period. Corticosteroid will be adminstered on the day prior to, on the day, and on the day after infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin 75mg/m2
Description: Cisplatin will be administered as an intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC0010
Description: 300mg, orally, BID
Study: NCT02410590

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisatracurium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine/Atropine
Study: NCT02138058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive restructuring intervention
Description: 4 sessions of a manualized cognitive restructuring intervention for compulsive buying

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive restructuring intervention
Description: 4 sessions of a manualized cognitive restructuring intervention for compulsive buying
Study: NCT03361930

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle-foot orthosis
Description: Two custom ankle-foot orthoses for the involved lower leg; cast, rectified and fitted by same certified orthotist to reduce clinician variability.~The cast is rectified according to the specifications of Hylton (1987) to produce tone-reducing features in the foot plate; the tone-reducing ankle-foot orthosis is manufactured on this cast. The orthotist then remodels the cast with a flat foot plate; the plain ankle-foot orthosis is then manufactured.
Study: NCT00244478

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy Protein Dietary Supplement
Description: The soy-based meal replacements will contain 20 g soy protein and 161.2 mg isoflavones, 220-240 kcal, 31-36 g total carbohydrates, 0-2 g dietary fiber, 500 mg calcium, and 2.0-2.5 g total fat per serving.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control shake will have 20 g casein substituted for soy protein, and will be otherwise identical to the soy shakes. The shakes will be available in two flavors: chocolate and vanilla.
Study: NCT04260971

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Abbott St Jude Medical Infinity 7 neurostimulator
Description: The stimulator has the capability to deliver both continuous and cyclical modes of stimulation which is being investigated in this study

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abbott St Jude Medical Infinity 7 neurostimulator
Description: The stimulator has the capability to deliver both continuous and cyclical modes of stimulation which is being investigated in this study
Study: NCT02787408

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EW Tricuspid Transcatheter Repair System
Description: Treatment with the EW Tricuspid Transcatheter Repair System
Study: NCT06548308

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Corneal Incision
Description: Astigmatism will be assessed by objective and subjective refraction by using the Autorefrectometer and retinoscop.Autorefrectometer uses to acsess the refracive state of eye by which we measure the astigmatim in patients eyes .Then after ctaract surgry in the next followup we will again use autorefrectometer to take readings and these both will be compared on visits among patients undergoing two procedures.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Toric Intraocular
Description: Two cataract surgery techniques will be used .1 : Toric IOL lenses designed with a unique shape to help provide clear vision at all distances for individuals with astigmatism compared to give better results specially in astigmatic patients.2: Corneal Inscion is which eye surgeon makes a very small opening on the eye, next to the outer corner. to remove the catract during surgry .
Study: NCT04156958

Intervention type: DRUG
Group type: OTHER
Intervention: Fruquintinib
Description: Fruquintinib will be administered orally at a dose of 5 mg/d, 3 weeks on, 1 week off (4 weeks as a cycle) until progression, unacceptable toxicity, or withdrawal unless toxicity not relieved after dose adjustment.
Study: NCT03613727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) and oral Vitamin C
Description: Intravenous (IV) vitamin C 50 mg/kg/day divided in 3 doses beginning on posttransplant Day +1 and continuing through Day +14; each dose (16.7 mg/kg) given in 50 mL of 5% dextrose and water over 30 minutes every 8 hours~• After completion of the IV vitamin C doses, oral vitamin C 500 mg twice each day beginning on Day +15 and continuing until Day +180
Study: NCT01922804

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: K2 vitamin
Description: K2 vitamin tablet
Study: NCT02410590

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Succinylcholine